Family-based Telemedicine vs. Inpatient Anorexia Nervosa Treatment (FIAT)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-17
SponsorCharite University, Berlin, Germany

About this trial

The FIAT study is funded by the Innovationsfonds of the German Ministry of Health via the DLR Project Management Agency. The study will be conducted in up to 21 hospitals across Germany and in collaboration with 10 German public health insurance companies. The primary aim of this study is to compare Family-Based Treatment delivered via telehealth (FBT) with inpatient multimodal therapy (IMT) with respect to treatment outcomes and health economic data. The results of the study will serve as a basis for the decision on the inclusion of FBT in the German S3 guidelines and the future reimbursement of FBT by public health insurances in Germany.

Eligibility criteria

Qualifiers

restrictive and bulimic subtypes of anorexia nervosa (ICD-10: F50.00; F50.01)

inpatient treatment indication according to S3 guideline

weight < 3. BMI-percentile or

weight <10. percentile and psychiatric comorbidity/rapid weight loss/lack of weight gain during outpatient treatment over last three month

Disqualifiers

weight <67%mBMI

acute self harm or danger to others

acute psychosis or suicidal tendencies

current substance abuse

Trial design

Treatments tested in this trial

  • Family based treatment
  • Inpatient multimodal therapy

Treatment groups

200 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Charite University, Berlin, Germany

Lead sponsor

Bielefeld University

Collaborator

Techniker Krankenkasse

Collaborator

BARMER

Collaborator

AOK Niedersachsen

Collaborator

Mobil Krankenkasse

Collaborator

Meine Krankenkasse

Collaborator

Medicalnetworks CJ GmbH & Co.KG

Collaborator

AOK Baden-Württemberg

Collaborator

DAK Gesundheit

Collaborator

BIG-direkt

Collaborator

mhplus

Collaborator

Bahn-BKK

Collaborator

OFFIS - Institut für Informatik

Collaborator

Prof. Daniel Le Grange, UCSF

Collaborator